CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients

Table 1

Patient characteristics.

Number of patients	200
Age
(median, range), yrs	34, 1–60
Adults > 16 yrs	174
Children ≤ 16 yrs	26
Recipient gender
Female	91
Male	109
Donor gender
Female	83
Male	116
Donor
Sibling	78
Unrelated HLA matched (10/10 at the allele level),	78
Mismatched, at the allele or low resolution levels up to two mismatches	44
Transplant material
Bone marrow (BM)	28
Peripheral blood progenitor cells (PBPC)	172
Diagnosis
Hematological malignancies (HM)	175
Chronic myeloid leukemia (CML)	24
Chronic lymphocytic leukemia (CLL)	5
Acute myeloid leukemia (AML)	67
Acute lymphocytic leukemia (ALL)	39
Other HM	40
Anemias and immunodeficiencies	24
Osteopetrosis	1
Conditioning regimen
Myeloablative	105
Reduced intensity conditioning (RIC)	95
Acute GvHD, grades
0	114
I	21
II	26
III	16
IV	23
Chronic GvHD
Extensive	38
Limited	33
EBV ≥100 DNA copies/10^5 cells	45/187
CMV ≥100 DNA copies/10^5 cells	54/187
HHV6 ≥100 DNA copies/10^5 cells	34/187
Polyoma (JC/BK)	19/33
CMV IgG serostatus
Recipients
CMV IgG negative	32
CMV IgG positive	168
Donors
CMV IgG negative	66
CMV IgG positive	132
Recipient/donor CMV serostatus
Recipient CMV IgG (+)/donor CMV IgG (+)	118
Recipient CMV IgG (−)/donor CMV IgG (−)	18
Recipient CMV IgG (+)/donor CMV IgG (−)	48
Recipient CMV IgG (−)/donor CMV IgG (+)	14